Multi‐phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations

Abstract

Background

Multi‐phenotype analysis of genetically correlated phenotypes can increase the statistical power to detect loci associated with multiple traits, leading to the discovery of novel loci. This is the first study to date to comprehensively analyze the shared genetic effects within different hemostatic traits, and between these and their associated disease outcomes.

Objectives

To discover novel genetic associations by combining summary data of correlated hemostatic traits and disease events.

Methods

Summary statistics from genome wide‐association studies (GWAS) from seven hemostatic traits (factor VII [FVII], factor VIII [FVIII], von Willebrand factor [VWF] factor XI [FXI], fibrinogen, tissue plasminogen activator [tPA], plasminogen activator inhibitor 1 [PAI‐1]) and three major cardiovascular (CV) events (venous thromboembolism [VTE], coronary artery disease [CAD], ischemic stroke [IS]), were combined in 27 multi‐trait combinations using metaUSAT. Genetic correlations between phenotypes were calculated using Linkage Disequilibrium Score Regression (LDSC). Newly associated loci were investigated for colocalization. We considered a significance threshold of 1.85 × 10⁻⁹ obtained after applying Bonferroni correction for the number of multi‐trait combinations performed (n = 27).

Results

Across the 27 multi‐trait analyses, we found 4 novel pleiotropic loci (XXYLT1, KNG1, SUGP1/MAU2, TBL2/MLXIPL) that were not significant in the original individual datasets, were not described in previous GWAS for the individual traits, and that presented a common associated variant between the studied phenotypes.

Conclusions

The discovery of four novel loci contributes to the understanding of the relationship between hemostasis and CV events and elucidate common genetic factors between these traits.

Essentials.

• Multi‐phenotype analysis of genetically correlated phenotypes may lead to novel discoveries.

• Summary statistics of hemostatic traits and cardiovascular events were combined with metaUSAT.

• We identified four novel associations with a shared variant between the studied phenotypes.

• Our results shed light on the relationship between hemostatic traits and cardiovascular events.

1. INTRODUCTION

Genome‐wide association studies (GWAS) have identified dozens of loci underlying the variability of plasma levels for individual hemostatic traits. ¹ , ² , ³ , ⁴ , ⁵ , ⁶ , ⁷ , ⁸ Further, GWAS for venous thromboembolism (VTE), ⁹ , ¹⁰ coronary artery disease (CAD) ¹¹ , ¹² , ¹³ and ischemic stroke (IS), ¹¹ , ¹⁴  have discovered 34, 169, and 20 genetic risk loci associated with these cardiovascular (CV) events, respectively.

Results from GWAS indicate that several of these hemostatic traits are genetically correlated with each other, sharing genetic loci that regulate their plasma levels. ¹ , ⁴ , ⁵ , ⁶ , ⁷ , ⁸  There are also shared genetic loci between hemostatic traits and CV events, again suggesting common regulators and possibly a causal pathway between the hemostatic trait and the CV event. ⁴ , ⁷ , ⁸ , ⁹ , ¹² , ¹⁴  The common regulatory loci between traits—even if the traits are not causally associated with each other—can be used to advance discovery of novel genetic loci common to the traits. This discovery can be accomplished with multi‐phenotype methods that incorporate summary statistics from several GWAS, increasing the statistical power to detect loci affecting two or more phenotypes by increasing the effective sample size. ¹⁵ , ¹⁶ , ¹⁷

In the present study, we used summary statistics of published GWAS from 7 hemostatic traits (FVII, FVIII, VWF, FXI, fibrinogen, PAI‐1, tPA), and 3 CV events (VTE, CAD, IS) to calculate their genetic correlations and to conduct multi‐phenotype meta‐analyses to detect new genetic loci not previously known to be associated with these phenotypes.

2. METHODS

2.1. Study design and resources

The setting of the project is the Cohorts of Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium Hemostasis Working Group. ¹⁸  We used GWAS summary statistics from seven hemostatic traits (FVII (N = 27 495), FVIII (N = 32 610), VWF (N = 46 354), FXI (N = 16 169), fibrinogen (N = 120 246), PAI‐1 (N = 19 599), tPA (N = 26 929)), and three CV events (VTE (N cases = 30 234, N controls = 172 122), CAD (N cases = 172 122, N controls = 566 864), IS (N cases = 60 341, N controls = 454 450)) to perform multi‐phenotype analyses. Summary statistics of FVII, ¹ FVIII, ⁴  VWF, ⁴  VTE, ⁹ CAD ¹² , ¹³ , ¹⁹ and IS, ¹⁴ come from trans‐ethnic analyses, while summary statistics of FXI, ⁶ fibrinogen, ⁵ tPA ⁸ and PAI‐1 ⁷ are European ancestry only (additional information, including the sample sizes, detailed ancestry groups, confounders considered and data access URLs, of the phenotypes that have been used, is available in Supplementary Table S1). Summary statistics for FVII, FVIII, VWF, FXI, fibrinogen, tPA, PAI‐1, were obtained from the most recent CHARGE meta‐analysis data ¹⁸ and are available on dbGaP ²⁰ (Appendix A). Data for VTE was obtained from INVENT ⁹ consortium and is available on request from corresponding authors (Appendix B). Data from IS were obtained from the MEGASTROKE Consortium, ¹⁴ and is available at https://www.megastroke.org/ (Appendix C). For CAD, we used METAL to perform an inverse variance weighted meta‐analysis between previously combined data from CARDIoGRAMplusC4D Consortium ¹⁹ and UK Biobank datasets ¹² (available at https://data.mendeley.com/datasets/2zdd47c94h/1), and the Biobank Japan dataset available at https://humandbs.biosciencedbc.jp/en/hum0014‐v21 using METAL. All the included data have been published between December 2012 and October 2020. The overlap of individuals observed in our combinations of phenotypes ranges between 0 and 0.58. The overlap between the CARDIoGRAMplusC4D Consortium and UK Biobank datasets that were combined by other authors, and used in this project, was estimated to be <0.1 %. ¹²

2.2. Study of heritability and genetic correlation

We determined the heritability of each phenotype and genetic correlations (r_g ) between all pairs of hemostatic traits, between each hemostatic factor and the CV events and between all pairs of CV events, using linkage disequilibrium (LD) score regression (LDSC). ²¹ LDSC uses a regression analysis between LD scores and the summary statistics of GWAS to provide an estimate of the shared heritability between phenotypes. ²²  We used pre‐computed LD scores from the European population of 1000G project. ²³ A subset of the European‐ancestry summary statistics was used in this step for each trait except for CAD where the European‐only meta‐analysis was not available. Alleles were merged with the HapMap3 single nucleotide polymorphisms (SNPs) list, ²⁴ to avoid incompatibilities between phenotypes, as recommended by the authors, and missing variants were removed.

For the threshold of statistical significance for each genetic correlation, we applied a Bonferroni correction for multiple comparisons, considering all pairwise genetic correlations calculated (p <.05/45 = .001).

2.3. Multi‐phenotype analysis

We performed multi‐phenotype analyses using GWAS summary statistics from different combinations of traits using the metaUSAT R package. ¹⁷  metaUSAT is a statistical approach for testing genetic association with one or more phenotypes simultaneously, using only common variants between the phenotypes. metaUSAT allows summary data as input that includes overlapping samples, which can be a source of bias with other methods; further, it does not assume homogeneity of trait effects across studies. ¹⁷ Compared to similar methods, metaUSAT performs similarly while requiring less computational time. ²⁵

In total, we performed 27 multi‐phenotype analyses, considering all pairs of hemostatic traits that showed significant genetic correlations (p <.001) (Supplementary Table S2), pairs of combinations between each hemostatic trait and each of the three CV events, and other combinations included based on biological aspects of the analyzed proteins: Fibrinogen‐FVII‐FXI‐tPA were analyzed because all of them are synthesized in the liver —although tPA is mostly produced by endothelial cells, recent studies that focused on the basal plasma tPA activity have also demonstrated the effects of hepatic produced tPA in fibrinolysis—. ²⁶ Secondly, tPA was combined with FVIII and VWF, that are highly correlated, because it is known that these three phenotypes share loci like STXBP5 that are involved in endothelial exocytosis. ⁴ , ⁸ Finally, the combination of fibrinogen and FVII was included to potentially discover genetic insights to the antithrombin (AT) pathway. It is known that AT deficiency is a strong risk factor for VTE, and that AT inhibits the FVIIa‐tissue factor complex's activation of FX. ²⁷ , ²⁸  Moreover, AT modifies prothrombin's conversion of fibrinogen to fibrin. ²⁹ Given this evidence, we hypothesize that potential common loci that regulate AT, FVII and fibrinogen might arise from this combination. Figure 1 shows all combinations that were analyzed.

FIGURE 1.

Schematic representation of the 27 multi‐phenotype combinations

For a metaUSAT p‐value (pvalue_multivariate) to be declared statistically significant, it needed to exceed a Bonferroni correction of the traditional GWAS statistical significance threshold to account for multiple testing for 27 multi‐trait combinations: 5 × 10⁻⁸/27 = 1.85 × 10⁻⁹. For those variants with statistically significant metaUSAT p‐values, we defined a locus as the genomic region +/− 500 kb around the variant with the lowest p‐value and any other variants that were in LD of r ² > 0.2. We used HaploR R package to retrieve variants in LD with the lead variant in each locus (the variant with the lowest p‐value).

In order to identify novel associated loci, we considered the following steps (Figure 2): (1) we identified all loci that were statistically significant in the multi‐phenotype analysis (p‐value_multivariate <1.85 x 10⁻⁹) (significant loci); (2) among these, we identified all loci with a lead variant that was at least nominally significant for two of the individual datasets used in each combination of phenotypes (lead variant p‐value_univariate <.005) ³⁰ , ³¹ , ³² (significant loci driven by more than one phenotype); (3) among the loci from step 2, we then narrowed it down to loci that were new for at least one of the phenotypes used in the combination, defined as loci where no other variant in the locus had a p‐value lower than 5 × 10⁻⁸ (p‐value_univariate <5 × 10⁻⁸) in the GWAS we used, and the locus had not been previously detected in another GWAS for the same phenotypes (new loci for one of the phenotypes used in the combination); and (4) among the loci from step 3, we identified loci that were new for all the phenotypes used in the combination (new loci for all the phenotypes used in the combination). We used the GWAS catalog database, ³³ (available at https://www.ebi.ac.uk/gwas/docs/file‐downloads) to detect loci that were published in previous GWAS. We used HaploReg v4 ³⁴ to retrieve previous results and biological annotations from the lead variants.

FIGURE 2.

Schematic representation of the analysis plan for multi‐phenotype analyses

2.4. Trait‐trait colocalization

For novel loci that were new for all traits, we then performed additional colocalization analysis to look for the existence of common associated variants across multiple traits. We used COLOC ³⁵ for loci associated with pairs of traits, and the R package HyPrColoc ³⁶ for loci associated with more than two traits. We considered windows of +/− 500 kb around the lead variant to define loci. For each locus, COLOC returns posterior probabilities (PP) for 4 different hypotheses (H_n): PP_H0 (the locus is not associated with any of the traits), PP_H1/PP_H2 (the locus is only associated with one of the traits), PP_H3 (the locus is associated with both traits but there is no evidence of them sharing a causal variant), PP_H4 (the locus is associated with both traits and LD patterns suggest the existence of a causal variant). We considered pleiotropic loci those that reached a conditional probability of colocalization (CPC) (PP_H4 / (PP_H4 + PP_H3)) > 0.8, which is defined as the conditional probability of colocalization with one causal variant, assuming the existence of a signal in both traits. To consider pleiotropic loci in multiple traits, we performed colocalization using HyPrColoc, where posterior probabilities of colocalization > 0.7 were required. Regional plots for significant colocalizing loci were done using LocusCompare R package.

2.5. Trait‐tissues colocalization

In order to prioritize candidate causal genes, we used novel pleiotropic loci identified in previous steps and performed an additional trait‐expression colocalization analysis using RNAseq data from the Genotype‐Tissue Expression (GTEx) project. ³⁷ First, we identified the lead variants that were significant expression quantitative trait loci (eQTL) and splicing quantitative trait loci (sQTL) for all tissues in GTEx V8 (available at https://www.gtexportal.org/home/datasets). Then, we performed colocalization with HyPrColoc, ³⁶ between the two or more phenotypes and the GTEx eQTL and sQTL results, using the complete GTEx V8 files (available at https://console.cloud.google.com/storage/browser/gtex‐resources), in order to identify the functional tissue and elucidate on the biological mechanism causing the associations. We required a probability of colocalization > 0.7 to consider significant colocalization between traits and tissue expression.

We restricted eQTL and sQTL analyses to a subset of GTEx tissues that could be of interest in relation to CV events and hemostatic traits: vascular tissues (artery aorta, artery coronary, artery tibial) lipid metabolism related tissues (adipose subcutaneous, adipose visceral omentum), blood (whole blood) and liver. All loci that showed significant colocalization between at least two traits were analyzed for colocalization with tissue expression in those tissues.

3. RESULTS

3.1. Linkage disequilibrium score regression (LDSC)

Genetic correlations were calculated for every pair of phenotypes used, including hemostatic traits and CV events. In total, 45 genetic correlations were calculated, 24 of which presented nominal significant p‐values (p <.05) and seven were significant after applying multiple testing correction (p <.001). Among the seven genetic correlations that were significant, three were between hemostatic traits (VWF‐FVIII (r_g  = 0.86, p = 1.25 × 10⁻¹⁵), fibrinogen‐PAI‐1 (r_g  = 0.4, p = 9.29 × 10⁻⁵), fibrinogen‐tPA (r_g  = 0.28, p =  0.001)) and were used for multi‐phenotype analyses, 3 were between a CV event and a hemostatic trait (CAD‐fibrinogen (r_g  = 0.19, p = 6.6 × 10⁻⁶), CAD‐tPA (r_g  = 0.48, p = 4.9 × 10⁻⁷), CAD‐PAI‐1 (r_g  = 0.52, p = 4.55 × 10⁻⁶)) and one was between two CV events (CAD‐IS (r_g  = 0.5, p = 2.23 × 10⁻²²)). All genetic correlations are shown in a heatmap in Figure 3 and are available at Supplementary Table S2.

FIGURE 3.

Heatmap of the genetic correlations between the two traits used in the multi‐phenotype analyses. * Indicates traits are significantly correlated with a p‐value <.001.

3.2. Multi‐phenotype analysis results

Overall, we performed 27 multi‐phenotype analyses: three (FVIII‐VWF, fibrinogen‐tPA and fibrinogen‐PAI‐1) based on significant genetic correlations between pairs of phenotypes, three (fibrinogen‐FVII‐tPA‐FXI, fibrinogen‐FVII and VWF‐FVIII‐tPA) due to previously known common regulatory biological pathways, and 21 between combinations of each of the seven hemostatic traits (FVII, FVIII, VWF, FXI, fibrinogen, tPA, PAI‐1) and each of the three CV events (VTE, CAD, IS).

The number of significant loci remaining in each step is represented in Figure 2. In total, we found 1 015 significant loci across the 27 multi‐phenotype combinations (Supplementary Table S3). Among them, 129 loci were driven by more than one of the phenotypes used in the combination (Supplementary Table S4), and 82 of them were new associations for one of phenotypes of the combination (Supplementary Table S5).

We found four novel associations that were not significant in the original individual datasets and had not been described in previous GWAS of the same traits (Table 1). Additional information on these loci, including the complete COLOC and HyPrColoc results are available at Supplementary Table S6. Figure 4 contains graphic representations of the p‐values and regional plots for each of these 4 loci.

TABLE 1.

Summary of the four novel associations identified in the 27 multi‐phenotype analyses that were not significant in the individual datasets and previous GWAS

Marker Name	Traits	Variant	Effect Allele	MAF	Effect 1	Effect 2	Effect 3	Effect 4	Locus Name	p‐valuemultivariate	p‐valueunivariate 1	p‐valueunivariate 2	p‐valueunivariate 3	p‐valueunivariate 4	CPC b
3:194790434	VTE‐FVII	rs3796159	C	0.2684	0.0605	−0.0112	‐	‐	XXYLT1	1.78 × 10−9	6.77 × 10−6	5.15 × 10−6	‐	‐	0.9727
3:186459927	VTE‐FVIII	rs710446	T	0.4136	−0.0601	−0.012	‐	‐	KNG1	4.12 × 10−11	3.71 × 10−7	1.1 × 10−6	‐	‐	0.9962
19:19407718	CAD‐FIBR	rs10401969	T	0.0768	0.0386	−0.0089	‐	‐	SUGP1/MAU2	8 × 10−11	2.22 × 10−5	2.99 × 10−7	‐	‐	0.9827
7:72989390	FIBR‐FVII‐FXI‐TPA	rs11974409	A	0.1816	0.0035	0.0154	0.0079	0.023	TBL2/MLXIPL	3.22 × 10−11	.0019	1.87 x 10‐7	0.014737	1.71 x 10‐5	0.9896 a

^a Posterior probability FVII‐tPA.

^b Conditional probability of colocalization.

FIGURE 4.

A: Regional plots for rs3796159 variant on XXYLT1 gene on VTE (top) and FVII (bottom). B: Regional plots for rs710446 variant on KNG1 gene on VTE (top) and FVIII (bottom). C: Regional plots for rs10401969 on SUGP1 gene on CAD (top) and fibrinogen (bottom). D: Regional plots for rs11974409 on TBL2 gene on FVII (top) and TPA (bottom).

3.3. XXYLT1

We detected a newly associated locus, with lead variant rs3796159, a 3’ UTR variant in XXYLT1 gene, in the multi‐phenotype analysis between VTE and FVII. Significant colocalization analysis (CPC > 0.8) (Figure 4A) in this locus suggested the existence of a common variant as a regulator of both phenotypes, VTE and FVII. Colocalization analysis in tissues indicated that rs3796159 is a significant eQTL for XXYLT1 in five different tissues (adipose subcutaneous, adipose visceral omentum, artery aorta, artery coronary, artery tibial) and HyPrColoc results (Supplementary Table S7) showed a triple significant colocalization (Posterior probability > 0.7) in adipose subcutaneous, adipose visceral omentum, artery aorta and artery tibial tissues in the XXLYT1 gene.

3.4. KNG1

Although previously identified in a candidate gene experiment as a risk factor for thrombosis ³⁸ and suggestively associated in other GWAS for VTE, ³⁹ this work represents the first time that the KNG1 locus, with lead variant rs710446, has been significantly associated to risk of VTE and FVIII in GWAS. rs710446 is a missense variant in the KNG1 gene that causes an amino acid change at the position 581 (Ile581Thr). ⁴⁰ Colocalization results between VTE and FVIII (CPC > 0.8) suggest that rs710446 in KNG1 gene is associated both with FVIII and VTE (Figure 4B). Our results could not provide evidence for this variant being a significant eQTL or sQTL in any of the analyzed tissues which suggest an effect through protein function.

3.5. SUGP1/MAU2

CAD and fibrinogen multi‐trait analysis resulted in the identification of a novel association on SUGP1 gene (lead variant rs10401969, intronic). Colocalization analysis between CAD and fibrinogen (Figure 4C) implicated that there is a shared associated variant at this locus (CPC > 0.8), while the analysis in GTEx tissues (Supplementary Table S7) and colocalization using HyPrColoc indicated a significant triple colocalization between CAD, fibrinogen and the GTEx dataset in blood in MAU2 gene (Posterior probability > 0.7).

3.6. TBL2/MLXIPL

The multi‐phenotype combination of hemostatic proteins that are synthesized in the liver (fibrinogen‐FVII‐FXI‐tPA), revealed a new association on TBL2 gene (lead variant rs11974409, intronic). Although not reaching the significance threshold for the 4 phenotypes (Posterior probability > 0.8), significant colocalization results (Figure 4D) between FVII and tPA suggest that a shared causal variant regulates both phenotypes in this locus.

rs11974409 variant is an eQTL in adipose subcutaneous, adipose visceral omentum, artery aorta, and whole blood, and an sQTL in adipose subcutaneous and adipose visceral omentum tissues. HyPrColoc analysis results suggested the existence of a common causal variant that regulates FVII, tPA and the expression of three different genes (AC005089.1, MLXIPL, BCL7B) in adipose subcutaneous, adipose visceral omentum and blood tissues (Posterior probability > 0.7) (Supplementary Table S7), and a common causal variant that regulates FVII, tPA and the splicing of MLXIPL gene in adipose subcutaneous and adipose visceral omentum tissues (Posterior probability > 0.7) (Supplementary Table S8).

3.7. MYRF/TEMEM258/FADS1/FADS2

Additionally, a novel association on MYRF/TMEM258/FADS1/FADS2 locus was detected in the multi‐phenotype analysis between IS‐VWF. Although just below the limit of significance (p‐value_multivariate = 1.64 × 10⁻⁸) (Supplementary Table S6), MYRF/TMEM8/FADS1/FADS2 locus has also been identified in the combinations between VWF and the other two CV events (VTE and CAD), (lead variant rs174528, intronic in MYRF gene). This association was reported for VTE in a previous European GWAS ¹⁰ and also for CAD, ¹³ but has not been associated with VWF or IS before. The three colocalization analyses between VWF and the CV events (Supplementary Table S6) in this locus suggest the existence of a variant regulating all traits (CPC > 0.8). HyPrColoc analysis revealed significant colocalization (Posterior probability > 0.7) between VWF, VTE and FADS1 gene expression in artery tibial and liver tissues (Supplementary Table S7), while also suggested —not significantly— (0.7 > Posterior probability > 0.5) an effect in splicing regulation in adipose visceral omentum in FADS2 and FEN1 genes with VTE and CAD (Supplementary Table S8). We were unable to identify triple colocalizations between VWF, IS and gene regulation.

4. DISCUSSION

We performed a multi‐phenotype approach using correlated hemostatic traits and three CV events and detected four novel pleiotropic loci that had not been previously described in association with these hemostatic traits or CV events.

Given a common locus between two or more phenotypes, three scenarios are possible: (1) there are different causal variants associated with the different traits, (2) the same variant associates with the different traits separately (horizontal pleiotropy), or (3) the variant associates with one trait, which in turn causes association with another trait (vertical pleiotropy). ⁴¹  While our analyses did not allow to differentiate between horizontal and vertical pleiotropy, we have found evidence of common variants in the four new pleiotropic loci, which agrees with the previous notion that pleiotropy is common between variants associated with correlated disease traits. ⁴² Common genetic regulators, however, do not mean that the associated phenotypes are causally associated. Causal associations between related phenotypes can be explored through Mendelian randomization (MR) methods.

We found a total of 1015 significant loci across all the multi‐phenotype combinations. Among these, 129 were driven by more than one phenotype, of which 46 were found in combinations with CAD, 38 with VTE, 28 in combinations between hemostatic traits, and 16 with IS. Finally, among the 82 loci that were new for at least one of the phenotypes used in the combination, 30 were identified in combinations with CAD, 23 with VTE, 15 between hemostatic traits, and 13 with IS.

4.1. XXYLT1 and regulation of FVII

XXYLT1 codes for xyloside xylotransferase 1, an enzyme that elongates O‐linked glycans in the epidermal growth factor (EGF) repeats of O‐linked glycosylated proteins like FVII. ⁴³ However, the direction of the effect of this variant suggests a decrease in FVII levels for allele C and an increase in the risk of VTE. In addition, MR analyses previously performed between VTE and FVII did not conclusively identify FVII as a cause of VTE, ¹ which suggests that the common variant at this locus on xyloside xylotransferase 1 enzyme could be affecting both phenotypes independently, through expression of XXYLT1 in adipose subcutaneous, adipose visceral omentum, artery aorta or artery tibial tissues. In this direction, it is known that other coagulation factors, like factor IX, are also glycosylated in the EGF repeats. ⁴⁴ It would be plausible to speculate that XXYLT1 could affect FVII levels and also other EGF‐glycosylated proteins that would eventually modify VTE risk. Therefore, further research in this locus is recommended to fully understand the possible relationship between XXYLT1, FVII and VTE, and the possible effect that other hemostatic proteins could have in this association.

4.2. KNG1 and risk of VTE through FVIII levels

The protein encoded by this gene, Kininogen‐1 (KNG1), is the precursor of two other proteins, obtained through alternative splicing: high‐molecular‐weight kininogen (HMWK) and low‐molecular‐weight kininogen (LMWK). Through a process facilitated by Factor XII (FXII), the peptide bradykinin is cleaved from HMWK by the enzyme kallikrein. ⁴⁵

There is strong biological evidence that associate KNG1 gene with the coagulation system. ⁴⁰ , ⁴⁶ , ⁴⁷ HMWK, along with FXII and prekallikrein (PK) complex, conform the plasma kallikrein‐kinin system (KKS), that plays an important role in human physiology. The activation of KKS components results in the induction of genes and biomolecules that participate in blood coagulation, among other processes. ⁴⁸ , ⁴⁹ Bradykinin, on its turn, is an important molecule involved in vascular permeability and also in mechanism of pain. ⁴⁵

We have previously shown ⁶ , ⁵⁰ , ⁵¹ that the lead variant on KNG1 (rs710446) is also strongly associated to activated partial thromboplastin time (aPTT), prekallirein, FXI and coagulation activity of FVIII in a candidate gene experiment, indicating a pleiotropic effect of this gene on regulating the intrinsic pathway of coagulation, ⁵² resulting in modified risk of VTE.

Although the association with VTE has been demonstrated in candidate‐gene studies, ³⁸ the combination between VTE‐FVIII, enhanced the association, suggesting a plausible functional relationship between KNG1 and FVIII that had never been reported in GWAS. This association could be explained by a putative regulation of KNG1 also on FVIII, which would imply an effect of KNG1 on the common pathway of coagulation. Associations of KNG1 with the entire coagulation cascade, and not just the intrinsic pathway, have been proposed by others.72 The significant colocalization analysis between VTE and FVIII in this locus aligns with previous evidence and suggests that rs710446 affects the regulation of both phenotypes along with other related hemostatic phenotypes.

4.3. SUGP1/MAU2 and CAD risk through fibrinogen levels

CAD and fibrinogen multi‐trait analysis resulted in the identification of a new pleiotropic locus on SUGP1/MAU2 genes, with lead variant rs10401969. SUGP1/MAU2 is a pleiotropic locus that has been associated to lipid's metabolism traits levels (total cholesterol, apoliprotein B, triglycerides), liver related proteins levels (alanine transaminase, asparatate aminotransferase, alanine aminotransferase), blood‐related phenotypes (red cell distribution width, mean reticulocyte volume), type 2 diabetes and cirrhosis. ³³  This locus has also been associated to CAD in candidate gene studies in Chinese and Caucasian populations but never in GWAS studies. ⁵³ , ⁵⁴ SUGP1 codes for a protein called SURP and G patch domains‐containing protein 1 (SUGP1), that it is believed to function in pre‐mRNA splicing mechanisms. ⁵⁵  This is the first time that SUGP1 is associated with coagulation factors and colocalization results suggest that the common variant at this locus is regulating both, CAD and fibrinogen. The identification of our lead variant, rs10401969, as a significant eQTL for MAU2 gene in blood, and the identification of this locus in a significant colocalization between CAD, fibrinogen and eQTL data in blood, also suggests the existence of a variant regulating both phenotypes that would take place through the MAU2 gene expression. MAU2 codes for MAU2 chromatid cohesion factor homolog and has an important role in loading the cohesion complex to DNA. ⁵⁶ , ⁵⁷  MAU2 has never been associated to coagulation factor levels.

Fibrinogen levels have been found significantly higher in cases of CAD in epidemiological studies, ⁵⁸ , ⁵⁹ although MR studies have only been able to demonstrate a small causal effect using multi‐variant MR approaches. ⁶⁰ , ⁶¹ Further evidence is needed to clearly elucidate if the effect of this variant on SUGP1/MAU2 locus on CAD is through fibrinogen levels or if this locus influences both phenotypes in parallel.

4.4. Liver produced proteins and the TBL2/MLXIPL locus

The TBL2/MLXIPL locus has been associated with other phenotypes of interest related to lipids metabolism levels (triglycerides, high density lipoprotein, low density lipoprotein) and other liver related proteins levels (alkaline phosphatase, C‐reactive protein, gamma glutamyl transferase or alanine aminotransferase), ³³ but this is the first time that a variant located on TBL2 reaches the significance threshold in a GWAS involving hemostatic factors. Also, in a previous candidate gene study for FVII levels, the variant rs7777102, located upstream the MLXIPL gene and ~70 kb away rs11974409 (D’ = 0.85, R ² = 0.44, in 1000G project European population ⁵¹ ), was found associated to FVII. ⁵¹  TBL2 codes for an endoplasmic reticulum transmembrane protein called transducin (β)‐like 2 (TBL2) that, upon ER stress, interacts with PERK (PKR‐like ER‐resident kinase) and is able to regulate ATF4 (activation transcription factor 4) translation. It has also been demonstrated that TBL2 has a WD40 (beta‐transducin repeat) domain that is essential for the association with mRNA of ATF4. ⁶² , ⁶³  MLXIPL codes for Carbohydrate response element binding protein (ChREBP), a transcription factor highly enriched in the liver with a key role in lipids metabolism. ChREBP has also shown a response for glucose metabolites that change its cellular location and stability and also imply post‐translational modifications. ChREBP binds to several proteins that are crucial to induce its nuclear translocation or biding to nuclear receptors. ⁶⁴ Considering the previous results obtained in a candidate gene studies in FVII, ⁵¹ that associated this locus to FVII levels, together with the significant colocalization results between FVII and tPA, and the significant results also of HyPrColoc with several tissues, all suggest that the TBL2/MLXIPL locus has a pleiotropic effect on the expression of several hemostatic traits. The colocalization results in tissues suggest MLXIPL gene as a good candidate gene, with a common variant in this locus regulating MLXIPL expression and splicing in adipose visceral and adipose visceral omentum tissues, FVII levels, and TPA levels at the same time.

4.5. MYRF/TMEM258/FADS1/FADS2 and its effect on CV events

MYRF codes for a membrane‐associated transcription factor, that participates in the activation of myelin genes and that has been associated to brain development issues. ⁶⁵ , ⁶⁶ Previous GWAS have also associated the genomic region of MYRF and TMEM258 genes to hematologic and lipid metabolism traits. ³³  TMEM258 codes for a protein with two predicted transmembrane domains, with no clear function in vivo, that has been associated with endoplasmic reticulum stress when knocked out and as an important regulator of intestinal hemostasis. TMEM258 has also been described as a potential causal gene of cardiovascular traits and as a regulatory site of abdominal visceral fat. ⁶⁷ , ⁶⁸

Although not new for VTE and CAD, the identification of the same locus in the multi‐phenotype analyses with all 3 CV events and a hemostatic trait supports the idea that the MYRF/TMEM258/FADS1/FADS2 locus is common regulator. Significant colocalization results between VWF and the cardiovascular outcomes, also support this idea. Our effort to prioritize a causal gene through the colocalization analysis in different tissues, revealed that a common variant at this locus regulates expression of FADS1 gene in artery tibial and liver and the splicing regulation of FADS2, although the colocalization was not significant. FADS1 and FADS2 code for members of the fatty acid desaturase gene family that catalyze several steps in the formation of omega‐3 and omega‐6 fatty acids. ⁶⁹  The rs174547 variant located on FADS1, in high LD with our lead variant rs174528 (D’ = 1, R ² = 0.84) in the European population of 1000 Genomes project, ⁷⁰ has been implicated in the risk of suffering multiple CV events, including VTE, CAD and IS, in a previous MR study. ⁷¹ Our results clearly support a regulatory role of this locus on several CV events and suggest the involvement of VWF in the association between FADS1/FADS2 and CV events.

4.6. Strengths and limitations

This is the first systematic multi‐phenotype analysis using summary data for hemostatic traits related to CV events to increase power to detect loci associated with more than one related phenotype. We have leveraged data from the leading consortia worldwide analyzing genetics of hemostatic traits, VTE, CAD, and IS, often providing the largest datasets currently available. We consider this, one of the most major strengths of this work. Moreover, most phenotypes included trans‐ethnic population, which give a broader transferability of the results.

We are aware of the existence of several limitations in this work. First, there are notable differences between the sample sizes of the hemostatic traits used, the largest one being fibrinogen (N = 120 246 cases) and the smallest one PAI‐1 (N = 19 599), which leads to differences in statistical power between multi‐phenotype analyses. Second, we were limited to use summary statistics of mostly European origin to calculate genetic correlations, given the lack of good references in other populations to generate the LD scores, which implies that these results cannot be applied to global populations. LDSC filters out variants with low sample size. For some phenotypes this information was not available, and we used the maximum sample size of the phenotype. This could have created some error. Third, we are also aware that there are limitations associated with the use of GTEx data. This data has limited sample sizes that vary greatly from tissue to tissue. For example, the number of liver samples (N = 208) is considerably lower than the samples of tissues such as artery tibial (N = 584) or adipose subcutaneous (N = 581), which may end up in differences in power to detect associations. The lower numbers of liver samples may have affected our power to detect some of the identified variants as significant eQTL in the liver, and therefore the implication of causal tissues should be interpreted with caution. Finally, we are not providing functional validation of these results. Therefore, further experiments are needed to confirm the implication of the novel suggested loci in disease.

5. CONCLUSIONS

We have shown that the multi‐phenotype analysis of biologically related phenotypes expands discovery of newly associated loci. Using summary GWAS data from hemostasis and CV events, we identified four colocalizing novel loci that were not identified as statistically significant in the source datasets and have not been described in other GWAS of the phenotypes involved. Although our strategy does not allow to unequivocally identify the causal variant or variants at each locus, the colocalization results suggest the existence of common regulatory variants at the newly identified loci.

Some of these loci appear to represent genes that may simultaneously regulate more than one hemostatic trait (horizontal pleiotropy), and some seem to reflect the risk mechanism from a gene to one or more CV events through regulation of a hemostatic factor (vertical pleiotropy), ⁴¹ therefore revealing novel biological mechanisms. Both cases of pleiotropy are novel interesting insights that will help understand the pathophysiology of clinical CV events.

CONFLICT OF INTEREST

S.M. Damrauer is named as a co‐inventor on a government‐owned US Patent application related to the use of genetic risk prediction for venous thromboembolic disease filed by the US Department of Veterans Affairs in accordance with Federal regulatory requirements. All other authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTIONS

M. Sabater‐Lleal, N.L Smith and P.S. de Vries conceived and designed the study and provided access to the data. G. Temprano‐Sagrera performed, analyzed, and interpreted the data and drafted the manuscript. C. M. Sitlani, W. P. Bone, and M. Martin‐Bornez, analyzed data and contributed to method selection and interpretation. B. F. Voight, A. C. Morrison, S. M. Damrauer, P. S. de Vries N. L. Smith and M. Sabater‐Lleal contributed to writing and editing the manuscript. All the authors revised and approved the final version of the manuscript.

Supporting information

Table S1

Table S2

Table S3

Table S4

Table S5

Table S6

Table S7

Table S8

APPENDIX A.

Abbas Dehghan¹, Adam SHeath², Alanna CMorrison², Alex PReiner³, Andrew Johnson⁴, Anne Richmond⁵, Annette Peters⁶, Astrid van Hylckama Vlieg⁷ Barbara McKnight⁸, Bruce MPsaty⁹, Caroline Hayward⁵, Cavin Ward‐Caviness¹⁰, Christopher O’Donnell¹¹, Daniel Chasman¹², David PStrachan¹³, David ATregouet¹⁴, Dennis Mook‐Kanamori⁷, Dipender Gill¹, Florian Thibord⁴, Folkert WAsselbergs¹⁵, Frank W.G. Leebeek¹⁶, Frits RRosendaal⁷, Gail Davies¹⁷, Georg Homuth¹⁸, Gerard Temprano¹⁹, Harry Campbell²⁰, Herman ATaylor²¹, Jan Bressler², Jennifer EHuffman²², Jerome IRotter²¹, Jie Yao²¹, James FWilson⁵, Joshua CBis²³, Julie MHahn², Karl CDesch²⁴, Kerri LWiggins²³, Laura MRaffield²⁵, Lawrence FBielak²⁶, Lisa RYanek²⁷, Marcus EKleber²⁸, Maria Sabater‐Lleal¹⁹, Martina Mueller⁶, Maryam Kavousi²⁹, Massimo Mangino³⁰, Melissa Liu⁴, Michael RBrown², Matthew PConomos⁸, Min‐A Jhun²⁶, Ming‐Huei Chen⁴, Moniek P.M. de Maat¹⁶, Nathan Pankratz³¹, Nicholas LSmith³, Patricia APeyser²⁶, Paul Elliot¹, Paul Sde Vries², Peng Wei³², Philipp SWild³³, Pierre EMorange³⁴, Pim van der Harst³⁵, Qiong Yang³⁶, Ngoc‐Quynh Le¹⁹, Riccardo Marioni³⁷, Ruifang Li⁷, Scott MDamrauer³⁸, Simon RCox¹⁷, Stella Trompet³⁹, Stephan BFelix⁴⁰, Uwe Völker¹⁸, Weihong Tang⁴¹, Wolfgang Koenig⁴², J. Wouter Jukema⁴³, Xiuqing Guo²¹.

¹Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. ²Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences; School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA. ³Department of Epidemiology, University of Washington, Seattle, WA, USA. ⁴National Heart Lung and Blood Institute, Division of Intramural Research, Population Sciences Branch, The Framingham Heart Study, Framingham, MA, USA. ⁵MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, Scotland. ⁶Research Unit Molecular Epidemiology, Helmholtz Zentrum München, München, Germany. ⁷Department of Clinical Epidemiology, Leiden University Medical Center, the Netherlands. ⁸Department of Biostatistics, University of Washington, Seattle, WA. ⁹Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, United States. ¹⁰Office of Research and Development, U.S. Environmental Protection Agency, Chapel Hill, NC, USA. ¹¹Cardiology, VA Boston Healthcare System, Boston, MA, USA. ¹²Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA. ¹³Population Health Research Institute, St George's University of London, London, UK. ¹⁴Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France. ¹⁵Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. ¹⁶Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands. ¹⁷Lothian Birth Cohorts, Department of Psychology, University of Edinburgh, Edinburgh, UK. ¹⁸Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. ¹⁹Unit of Genomics of Complex Diseases. Sant Pau Biomedical Research Institute (IIB‐Sant Pau), Barcelona, Spain. ²⁰Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland, UK. ²¹The Institute for Translational Genomics and Population Sciences, Department of Pediatrcs, The Lundquist Institute for Biomedical Innovation at Harbor‐UCLA Medical Center, Torrance, CA USA. ²²Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA. ²³Cardiovascular Health Research Unit Department of Medicine University of Washington Seattle Washington USA. ²⁴Department of Pediatrics, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, MI, USA. ²⁵Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ²⁶Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI. ²⁷Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ²⁸SYNLAB MVZ für Humangenetik Mannheim, Mannheim, Germany. ²⁹Department of Epidemiology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, Netherlands. ³⁰Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK. ³¹Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN, USA. ³²Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston. ³³Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany. ³⁴Hematology Laboratory, La Timone University Hospital of Marseille, Marseille, France. ³⁵Department of Cardiology, University Medical Center Utrecht, Utrecht, Netherlands. ³⁶Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. ³⁷Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. ³⁸Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ³⁹Section of Gerontology and Geriatrics, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands. ⁴⁰Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany. ⁴¹School of Public Health, University of Minnesota, Minneapolis, MN, USA. ⁴²DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. ⁴³Department of Cardiology, Leiden University Medical Center, The Netherlands.

APPENDIX B.

Sara Lindstrom, PhD¹, Lu Wang, PhD², Erin NSmith, PhD³, William Gordon, MS⁴, Astrid van Hylckama Vlieg, PhD⁵, Mariza de Andrade, PhD⁶, Jennifer ABrody, BA⁷, Jack WPattee, BA⁸, Jeffrey Haessler, MS⁹, Ben MBrumpton, PhD, MPH¹⁰, Daniel IChasman, PhD¹¹, Pierre Suchon, MD‐PhD¹², Ming‐Huei Chen, PhD¹³, Constance Turman, MS¹⁴, Marine Germain¹⁵, Kerri LWiggins, MS, RD¹⁶, James MacDonald, MS¹⁷, Sigrid KBraekkan, PhD¹⁸, Sebastian MArmasu, MS¹⁹, Nathan Pankratz, PhD²⁰, Rabecca DJackson, MD²¹, Jonas BNielsen, MD, PhD²², Franco Giulianini, PhD²³, Marja KPuurunen, MD, PhD²⁴, Manal Ibrahim, MD²⁵, Susan RHeckbert, MD, PhD²⁶, Theo KBammler, PhD²⁷, Kelly AFrazer, PhD²⁸, Bryan MMcCauley, MS²⁹, Kent Taylor, PhD³⁰, James SPankow, PhD, MPH³¹, Alexander PReiner, MD, MPH³², Maiken EGabrielsen, PhD³³, Jean‐François Deleuze, PhD³⁴, Chris JO'Donnell, MD³⁵, Jihye Kim, PhD, MPH³⁶, Barbara McKnight, PhD³⁷, Peter Kraft, PhD³⁸, John‐Bjarne Hansen, MD, PhD³⁹, Frits RRosendaal, MD, PhD⁴⁰, John AHeit, MD⁴¹, Bruce MPsaty, MD, PhD⁴², Weihong Tang, MD, PhD⁴³, Charles Kooperberg, PhD⁴⁴, Kristian Hveem, MD, PhD⁴⁵, Paul MRidker, MD, MPH⁴⁶, Pierre‐Emmanuel Morange, MD‐PhD⁴⁷, Andrew DJohnson, PhD⁴⁸, Christopher Kabrhel, MD MPH⁴⁹, David‐Alexandre Trégouët, PhD⁵⁰, Nicholas LSmith, PhD⁵¹.

Author Affiliations: ¹Department of Epidemiology, University of Washington, Seattle, Washington, USA; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ²Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA. ³Department of Pediatrics and Rady Children's Hospital, University of California San Diego, La Jolla, USA; K.G. Jebsen Thrombosis Research and Expertise Center, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway. ⁴Department of Epidemiology, University of Washington, Seattle, WA, USA. ⁵Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. ⁶Department of Health Sciences Research, Mayo Clinic, Rochester, MN USA. ⁷Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle WA USA. ⁸Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN USA. ⁹Division of Public Health, Fred Hutchinson Cancer Research Center, Seattle WA, USA. ¹⁰K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK; Clinic of Thoracic and Occupational Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. ¹¹Division of Preventive Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA. ¹²Laboratory of Haematology, La Timone Hospital, Marseille, France; C2VN, Aix Marseille University, INSERM, INRA, C2VN, Marseille, France. ¹³Population Sciences Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, Bethesda, MD, USA; NHLBI and Boston University's The Framingham Heart Study, Framingham, MA, USA. ¹⁴Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ¹⁵INSERM UMR_S 1219, Bordeaux Population Health Research Center, University of Bordeaux, France. ¹⁶Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle WA USA. ¹⁷Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA. ¹⁸K.G. Jebsen Thrombosis Research and Expertise Center, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway; Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway. ¹⁹Health Sciences Research, Mayo Clinic, Rochester, MN USA. ²⁰Department of Laboratory Medicine and Pathology, School of Medicine, University of Minnesota, Minneapolis, MN, USA. ²¹Division of Endocrinology, Diabetes and Metabolism, The Ohio State University, Columbus OH, USA. ²²Department of Internal Medicine, Division of Cardiology, University of Michigan Medical School, Ann Arbor, Michigan, USA. ²³Division of Preventive Medicine, Brigham and Women's Hospital, Boston, USA. ²⁴NHLBI and Boston University's The Framingham Heart Study, Framingham, MA, USA. ²⁵Laboratory of Haematology, La Timone Hospital, Marseille, France.; C2VN, Aix Marseille University, INSERM, INRA, C2VN, Marseille, France. ²⁶Department of Epidemiology, University of Washington, Seattle, Washington, USA; Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle WA USA. ²⁷Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA. ²⁸Department of Pediatrics and Rady Children's Hospital, University of California San Diego, La Jolla, USA; K.G. Jebsen Thrombosis Research and Expertise Center, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway; Institute of Genomic Medicine, University of California San Diego, La Jolla, California, USA. ²⁹Health Sciences Research, Mayo Clinic, Rochester, MN USA. ³⁰Los Angeles Biomedical Research Institute and Department of Pediatrics, Harbor‐UCLA Medical Center, Torrence CA 90502, USA. ³¹Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA. ³²Department of Epidemiology, University of Washington, Seattle WA, United States; Division of Public Health, Fred Hutchinson Cancer Research Center, Seattle WA, United States. ³³K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. ³⁴Centre National de Recherche en Génomique Humaine, Direction de la Recherche Fondamentale, CEA, 91057 Evry, France; CEPH, Fondation Jean Dausset, Paris, France. ³⁵Million Veteran's Program, Veteran's Administration, Boston, MA; Population Sciences Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, Bethesda, MD, USA; NHLBI and Boston University's The Framingham Heart Study, Framingham, MA, USA. ³⁶Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ³⁷Department of Biostatistics, University of Washington, Seattle WA USA; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ³⁸Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ³⁹K.G. Jebsen Thrombosis Research and Expertise Center, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway; Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway. ⁴⁰Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. ⁴¹Health Sciences Research, Mayo Clinic, Rochester, MN USA. ⁴²Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle WA USA; Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle WA USA. ⁴³Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA. ⁴⁴Division of Public Health, Fred Hutchinson Cancer Research Center, Seattle WA, United States. ⁴⁵K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. ⁴⁶Division of Preventive Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA. ⁴⁷C2VN, Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France; Laboratory of Haematology, La Timone Hospital, Marseille, France; CRB Assistance Publique ‐ Hôpitaux de Marseille, HemoVasc (CRB AP‐HM HemoVasc), Marseille, France. ⁴⁸Population Sciences Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, Bethesda, MD, USA; NHLBI and Boston University's The Framingham Heart Study, Framingham, MA, USA. ⁴⁹Center for Vascular Emergencies, Department of Emergency Medicine, Massachusetts General Hospital; Channing Division of Network Medicine, Brigham and Women's Hospital; Harvard Medical School. ⁵⁰INSERM UMR_S 1219, Bordeaux Population Health Research Center, University of Bordeaux, France. ⁵¹Department of Epidemiology, University of Washington, Seattle, Washington, USA; Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle WA USA; Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research and Development, Seattle WA USA.

APPENDIX C.

Rainer Malik¹, Ganesh Chauhan², Matthew Traylor³, Muralidharan Sargurupremraj^4,5, Yukinori Okada^6,7,8, Aniket Mishra^4,5, Loes Rutten‐Jacobs³, Anne‐Katrin Giese⁹, Sander W van der Laan¹⁰, Solveig Gretarsdottir¹¹, Christopher D Anderson^12,13,14,14, Michael Chong¹⁵, Hieab HH Adams^16,17, Tetsuro Ago¹⁸, Peter Almgren¹⁹, Philippe Amouyel^20,21, Hakan Ay^22,13, Traci M Bartz²³, Oscar R Benavente²⁴, Steve Bevan²⁵, Giorgio B Boncoraglio²⁶, Robert D Brown, Jr.²⁷, Adam S Butterworth^28,29, Caty Carrera^30,31, Cara L Carty^32,33, Daniel I Chasman^34,35, Wei‐Min Chen³⁶, John W Cole³⁷, Adolfo Correa³⁸, Ioana Cotlarciuc³⁹, Carlos Cruchaga^40,41, John Danesh^28,42,43,44, Paul IW de Bakker^45,46, Anita L DeStefano^47,48, Marcel den Hoed⁴⁹, Qing Duan⁵⁰, Stefan T Engelter^51,52, Guido J Falcone^53,54, Rebecca F Gottesman⁵⁵, Raji P Grewal⁵⁶, Vilmundur Gudnason^57,58, Stefan Gustafsson⁵⁹, Jeffrey Haessler⁶⁰, Tamara B Harris⁶¹, Ahamad Hassan⁶², Aki S Havulinna^63,64, Susan R Heckbert⁶⁵, Elizabeth G Holliday^66,67, George Howard⁶⁸, Fang‐Chi Hsu⁶⁹, Hyacinth I Hyacinth⁷⁰, M Arfan Ikram¹⁶, Erik Ingelsson^71,72, Marguerite R Irvin⁷³, Xueqiu Jian⁷⁴, Jordi Jiménez‐Conde⁷⁵, Julie A Johnson^76,77, J Wouter Jukema⁷⁸, Masahiro Kanai^6,7,79, Keith L Keene^80,81, Brett M Kissela⁸², Dawn O Kleindorfer⁸², Charles Kooperberg⁶⁰, Michiaki Kubo⁸³, Leslie A Lange⁸⁴, Carl D Langefeld⁸⁵, Claudia Langenberg⁸⁶, Lenore J Launer⁸⁷, Jin‐Moo Lee⁸⁸, Robin Lemmens^89,90, Didier Leys⁹¹, Cathryn M Lewis^92,93, Wei‐Yu Lin^28,94, Arne G Lindgren^95,96, Erik Lorentzen⁹⁷, Patrik K Magnusson⁹⁸, Jane Maguire⁹⁹, Ani Manichaikul³⁶, Patrick F McArdle¹⁰⁰, James F Meschia¹⁰¹, Braxton D Mitchell^100,102, Thomas H Mosley^103,104, Michael A Nalls^105,106, Toshiharu Ninomiya¹⁰⁷, Martin J O'Donnell^15,108, Bruce M Psaty^{109,110,111,112}, Sara L Pulit^113,45, Kristiina Rannikmäe^114,115, Alexander P Reiner^65,116, Kathryn M Rexrode¹¹⁷, Kenneth Rice¹¹⁸, Stephen S Rich³⁶, Paul M Ridker^34,35, Natalia S Rost^9,13, Peter M Rothwell¹¹⁹, Jerome I Rotter^120,121, Tatjana Rundek¹²², Ralph L Sacco¹²², Saori Sakaue^7,123, Michele M Sale¹²⁴, Veikko Salomaa⁶³, Bishwa R Sapkota¹²⁵, Reinhold Schmidt¹²⁶, Carsten O Schmidt¹²⁷, Ulf Schminke¹²⁸, Pankaj Sharma³⁹, Agnieszka Slowik¹²⁹, Cathie LM Sudlow^114,115, Christian Tanislav¹³⁰, Turgut Tatlisumak^131,132, Kent D Taylor^120,121, Vincent NS Thijs^133,134, Gudmar Thorleifsson¹¹, Unnur Thorsteinsdottir¹¹, Steffen Tiedt¹, Stella Trompet¹³⁵, Christophe Tzourio^5,136,137, Cornelia M van Duijn^138,139, Matthew Walters¹⁴⁰, Nicholas J Wareham⁸⁶, Sylvia Wassertheil‐Smoller¹⁴¹, James G Wilson¹⁴², Kerri L Wiggins¹⁰⁹, Qiong Yang⁴⁷, Salim Yusuf¹⁵, Najaf Amin¹⁶, Hugo S Aparicio^185,48, Donna K Arnett¹⁸⁶, John Attia¹⁸⁷, Alexa S Beiser^47,48, Claudine Berr¹⁸⁸, Julie E Buring^34,35, Mariana Bustamante¹⁸⁹, Valeria Caso¹⁹⁰, Yu‐Ching Cheng¹⁹¹, Seung Hoan Choi^192,48, Ayesha Chowhan^185,48, Natalia Cullell³¹, Jean‐François Dartigues^193,194, Hossein Delavaran^95,96, Pilar Delgado¹⁹⁵, Marcus Dörr^196,197, Gunnar Engström¹⁹, Ian Ford¹⁹⁸, Wander S Gurpreet¹⁹⁹, Anders Hamsten^200,201, Laura Heitsch²⁰², Atsushi Hozawa²⁰³, Laura Ibanez²⁰⁴, Andreea Ilinca^95,96, Martin Ingelsson²⁰⁵, Motoki Iwasaki²⁰⁶, Rebecca D Jackson²⁰⁷, Katarina Jood²⁰⁸, Pekka Jousilahti⁶³, Sara Kaffashian^4,5, Lalit Kalra²⁰⁹, Masahiro Kamouchi²¹⁰, Takanari Kitazono²¹¹, Olafur Kjartansson²¹², Manja Kloss²¹³, Peter J Koudstaal²¹⁴, Jerzy Krupinski²¹⁵, Daniel L Labovitz²¹⁶, Cathy C Laurie¹¹⁸, Christopher R Levi²¹⁷, Linxin Li²¹⁸, Lars Lind²¹⁹, Cecilia M Lindgren^220,221, Vasileios Lioutas^222,48, Yong Mei Liu²²³, Oscar L Lopez²²⁴, Hirata Makoto²²⁵, Nicolas Martinez‐Majander¹⁷², Koichi Matsuda²²⁵, Naoko Minegishi²⁰³, Joan Montaner²²⁶, Andrew P Morris^227,228, Elena Muiño³¹, Martina Müller‐Nurasyid^229,230,231, Bo Norrving^95,96, Soichi Ogishima²⁰³, Eugenio A Parati²³², Leema Reddy Peddareddygari⁵⁶, Nancy L Pedersen^98,233, Joanna Pera¹²⁹, Markus Perola^63,234, Alessandro Pezzini²³⁵, Silvana Pileggi²³⁶, Raquel Rabionet²³⁷, Iolanda Riba‐Llena³⁰, Marta Ribasés²³⁸, Jose R Romero^185,48, Jaume Roquer^239,240, Anthony G Rudd^241,242, Antti‐Pekka Sarin^243,244, Ralhan Sarju¹⁹⁹, Chloe Sarnowski^47,48, Makoto Sasaki²⁴⁵, Claudia L Satizabal^185,48, Mamoru Satoh²⁴⁵, Naveed Sattar²⁴⁶, Norie Sawada²⁰⁶, Gerli Sibolt¹⁷², Ásgeir Sigurdsson²⁴⁷, Albert Smith²⁴⁸, Kenji Sobue²⁴⁵, Carolina Soriano‐Tárraga²⁴⁰, Tara Stanne²⁴⁹, O Colin Stine²⁵⁰, David J Stott²⁵¹, Konstantin Strauch^229,252, Takako Takai²⁰³, Hideo Tanaka^253,254, Kozo Tanno²⁴⁵, Alexander Teumer²⁵⁵, Liisa Tomppo¹⁷², Nuria P Torres‐Aguila³¹, Emmanuel Touze^256,257, Shoichiro Tsugane²⁰⁶, Andre G Uitterlinden²⁵⁸, Einar M Valdimarsson²⁵⁹, Sven J van der Lee¹⁶, Henry Völzke²⁵⁵, Kenji Wakai²⁵³, David Weir²⁶⁰, Stephen R Williams²⁶¹, Charles DA Wolfe^241,242, Quenna Wong¹¹⁸, Huichun Xu¹⁹¹, Taiki Yamaji²⁰⁶, Dharambir K Sanghera^125,169,170, Olle Melander¹⁹, Christina Jern¹⁷¹, Daniel Strbian^172,173, Israel Fernandez‐Cadenas^31,30, W T Longstreth, Jr^174,65, Arndt Rolfs¹⁷⁵, Jun Hata¹⁰⁷, Daniel Woo⁸², Jonathan Rosand^12,13,14, Guillaume Pare¹⁵, Jemma C Hopewell¹⁷⁶, Danish Saleheen¹⁷⁷, Kari Stefansson^11,178, Bradford B Worrall¹⁷⁹, Steven J Kittner³⁷, Sudha Seshadri^180,48, Myriam Fornage^74,181, Hugh S Markus³, Joanna MM Howson²⁸, Yoichiro Kamatani^6,182, Stephanie Debette^4,5, Martin Dichgans^1,183,184.

¹Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany. ²Centre for Brain Research, Indian Institute of Science, Bangalore, India. ³Stroke Research Group, Division of Clinical Neurosciences, University of Cambridge, UK. ⁴INSERM U1219 Bordeaux Population Health Research Center, Bordeaux, France. ⁵University of Bordeaux, Bordeaux, France. ⁶Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ⁷Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan. ⁸Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI‐IFReC), Osaka University, Suita, Japan. ⁹Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ¹⁰Laboratory of Experimental Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands. ¹¹deCODE genetics/AMGEN inc, Reykjavik, Iceland. ¹²Center for Genomic Medicine, Massachusetts General Hospital (MGH), Boston, MA, USA. ¹³J. Philip Kistler Stroke Research Center, Department of Neurology, MGH, Boston, MA, USA. ¹⁴Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA. ¹⁵Population Health Research Institute, McMaster University, Hamilton, Canada. ¹⁶Department of Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands. ¹⁷Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, Netherlands. ¹⁸Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ¹⁹Department of Clinical Sciences, Lund University, Malmö, Sweden. ²⁰Univ. Lille, Inserm, Institut Pasteur de Lille, LabEx DISTALZ‐UMR1167, Risk factors and molecular determinants of aging‐related diseases, F‐59000 Lille, France. ²¹Centre Hosp. Univ Lille, Epidemiology and Public Health Department, F‐59000 Lille, France. ²²AA Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ²³Cardiovascular Health Research Unit, Departments of Biostatistics and Medicine, University of Washington, Seattle, WA, USA. ²⁴Division of Neurology, Faculty of Medicine, Brain Research Center, University of British Columbia, Vancouver, Canada. ²⁵School of Life Science, University of Lincoln, Lincoln, UK. ²⁶Department of Cerebrovascular Diseases, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milano, Italy. ²⁷Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA. ²⁸MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ²⁹The National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, UK. ³⁰Neurovascular Research Laboratory, Vall d'Hebron Institut of Research, Neurology and Medicine Departments‐Universitat Autònoma de Barcelona, Vall d’Hebrón Hospital, Barcelona, Spain. ³¹Stroke Pharmacogenomics and Genetics, Fundacio Docència i Recerca MutuaTerrassa, Terrassa, Spain. ³²Children's Research Institute, Children's National Medical Center, Washington, DC, USA. ³³Center for Translational Science, George Washington University, Washington, DC, USA. ³⁴Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA. ³⁵Harvard Medical School, Boston, MA, USA. ³⁶Center for Public Health Genomics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA. ³⁷Department of Neurology, University of Maryland School of Medicine and Baltimore VAMC, Baltimore, MD, USA. ³⁸Departments of Medicine, Pediatrics and Population Health Science, University of Mississippi Medical Center, Jackson, MS, USA. ³⁹Institute of Cardiovascular Research, Royal Holloway University of London, UK & Ashford and St Peters Hospital, Surrey UK. ⁴⁰Department of Psychiatry, The Hope Center Program on Protein Aggregation and Neurodegeneration (HPAN), Washington University, School of Medicine, St. Louis, MO, USA. ⁴¹Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA. ⁴²NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ⁴³Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. ⁴⁴British Heart Foundation, Cambridge Centre of Excellence, Department of Medicine, University of Cambridge, Cambridge, UK. ⁴⁵Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands. ⁴⁶Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands. ⁴⁷Boston University School of Public Health, Boston, MA, USA. ⁴⁸Framingham Heart Study, Framingham, MA, USA. ⁴⁹Department of Immunology, Genetics and Pathology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. ⁵⁰Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. ⁵¹Department of Neurology and Stroke Center, Basel University Hospital, Switzerland. ⁵²Neurorehabilitation Unit, University and University Center for Medicine of Aging and Rehabilitation Basel, Felix Platter Hospital, Basel, Switzerland. ⁵³Department of Neurology, Yale University School of Medicine, New Haven, CT, USA. ⁵⁴Program in Medical and Population Genetics, The Broad Institute of Harvard and MIT, Cambridge, MA, USA. ⁵⁵Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ⁵⁶Neuroscience Institute, SF Medical Center, Trenton, NJ, USA. ⁵⁷Icelandic Heart Association Research Institute, Kopavogur, Iceland. ⁵⁸University of Iceland, Faculty of Medicine, Reykjavik, Iceland. ⁵⁹Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. ⁶⁰Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ⁶¹Laboratory of Epidemiology and Population Science, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. ⁶²Department of Neurology, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds, UK. ⁶³National Institute for Health and Welfare, Helsinki, Finland. ⁶⁴FIMM ‐ Institute for Molecular Medicine Finland, Helsinki, Finland. ⁶⁵Department of Epidemiology, University of Washington, Seattle, WA, USA. ⁶⁶Public Health Stream, Hunter Medical Research Institute, New Lambton, Australia. ⁶⁷Faculty of Health and Medicine, University of Newcastle, Newcastle, Australia. ⁶⁸School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA. ⁶⁹Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston‐Salem, NC, USA. ⁷⁰Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. ⁷¹Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, CA, USA. ⁷²Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. ⁷³Epidemiology, School of Public Health, University of Alabama at Birmingham, USA. ⁷⁴Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA. ⁷⁵Neurovascular Research Group (NEUVAS), Neurology Department, Institut Hospital del Mar d'Investigació Mèdica, Universitat Autònoma de Barcelona, Barcelona, Spain. ⁷⁶Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, College of Pharmacy, Gainesville, FL, USA. ⁷⁷Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL, USA. ⁷⁸Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands. ⁷⁹Program in Bioinformatics and Integrative Genomics, Harvard Medical School, Boston, MA, USA. ⁸⁰Department of Biology, East Carolina University, Greenville, NC, USA. ⁸¹Center for Health Disparities, East Carolina University, Greenville, NC, USA. ⁸²University of Cincinnati College of Medicine, Cincinnati, OH, USA. ⁸³RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ⁸⁴Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. ⁸⁵Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston‐Salem, NC, USA. ⁸⁶MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK. ⁸⁷Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. ⁸⁸Department of Neurology, Radiology, and Biomedical Engineering, Washington University School of Medicine, St. Louis, MO, USA. ⁸⁹KU Leuven – University of Leuven, Department of Neurosciences, Experimental Neurology, Leuven, Belgium. ⁹⁰VIB Center for Brain & Disease Research, University Hospitals Leuven, Department of Neurology, Leuven, Belgium. ⁹¹Univ.‐Lille, INSERM U 1171. CHU Lille, Lille, France. ⁹²Department of Medical and Molecular Genetics, King's College London, London, UK. ⁹³SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. ⁹⁴Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Newcastle, UK. ⁹⁵Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden. ⁹⁶Department of Neurology and Rehabilitation Medicine, Skåne University Hospital, Lund, Sweden. ⁹⁷Bioinformatics Core Facility, University of Gothenburg, Gothenburg, Sweden. ⁹⁸Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁹⁹University of Technology Sydney, Faculty of Health, Ultimo, Australia. ¹⁰⁰Department of Medicine, University of Maryland School of Medicine, MD, USA. ¹⁰¹Department of Neurology, Mayo Clinic, Jacksonville, FL, USA. ¹⁰²Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, MD, USA. ¹⁰³Division of Geriatrics, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA. ¹⁰⁴Memory Impairment and Neurodegenerative Dementia Center, University of Mississippi Medical Center, Jackson, MS, USA. ¹⁰⁵Laboratory of Neurogenetics, National Institute on Aging, National institutes of Health, Bethesda, MD, USA. ¹⁰⁶Data Tecnica International, Glen Echo MD, USA. ¹⁰⁷Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ¹⁰⁸Clinical Research Facility, Department of Medicine, NUI Galway, Galway, Ireland. ¹⁰⁹Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA. ¹¹⁰Department of Epidemiology, University of Washington, Seattle, WA. ¹¹¹Department of Health Services, University of Washington, Seattle, WA, USA. ¹¹²Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA. ¹¹³Brain Center Rudolf Magnus, Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands. ¹¹⁴Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK. ¹¹⁵Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. ¹¹⁶Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA. ¹¹⁷Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. ¹¹⁸Department of Biostatistics, University of Washington, Seattle, WA, USA. ¹¹⁹Nuffield Department of Clinical Neurosciences, University of Oxford, UK. ¹²⁰Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor‐UCLA Medical Center, Torrance, CA, USA. ¹²¹Division of Genomic Outcomes, Department of Pediatrics, Harbor‐UCLA Medical Center, Torrance, CA, USA. ¹²²Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA. ¹²³Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan. ¹²⁴Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA. ¹²⁵Department of Pediatrics, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. ¹²⁶Department of Neurology, Medical University of Graz, Graz, Austria. ¹²⁷University Medicine Greifswald, Institute for Community Medicine, SHIP‐KEF, Greifswald, Germany. ¹²⁸University Medicine Greifswald, Department of Neurology, Greifswald, Germany. ¹²⁹Department of Neurology, Jagiellonian University, Krakow, Poland. ¹³⁰Department of Neurology, Justus Liebig University, Giessen, Germany. ¹³¹Department of Clinical Neurosciences/Neurology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. ¹³²Sahlgrenska University Hospital, Gothenburg, Sweden. ¹³³Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Australia. ¹³⁴Austin Health, Department of Neurology, Heidelberg, Australia. ¹³⁵Department of Internal Medicine, Section Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands. ¹³⁶INSERM U1219, Bordeaux, France. ¹³⁷Department of Public Health, Bordeaux University Hospital, Bordeaux, France. ¹³⁸Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center Rotterdam, Netherlands. ¹³⁹Center for Medical Systems Biology, Leiden, Netherlands. ¹⁴⁰School of Medicine, Dentistry and Nursing at the University of Glasgow, Glasgow, UK. ¹⁴¹Department of Epidemiology and Population Health, Albert Einstein College of Medicine, NY, USA. ¹⁴²Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA. ¹⁴³A full list of members and affiliations appears in the Supplementary Note. ¹⁴⁴Department of Human Genetics, McGill University, Montreal, Canada. ¹⁴⁵Department of Pathophysiology, Institute of Biomedicine and Translation Medicine, University of Tartu, Tartu, Estonia. ¹⁴⁶Department of Cardiac Surgery, Tartu University Hospital, Tartu, Estonia. ¹⁴⁷Clinical Gene Networks AB, Stockholm, Sweden. ¹⁴⁸Department of Genetics and Genomic Sciences, The Icahn Institute for Genomics and Multiscale Biology Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁴⁹Department of Pathophysiology, Institute of Biomedicine and Translation Medicine, University of Tartu, Biomeedikum, Tartu, Estonia. ¹⁵⁰Integrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institutet, Karolinska Universitetssjukhuset, Huddinge, Sweden. ¹⁵¹Clinical Gene Networks AB, Stockholm, Sweden. ¹⁵²Sorbonne Universités, UPMC Univ. Paris 06, INSERM, UMR_S 1166, Team Genomics & Pathophysiology of Cardiovascular Diseases, Paris, France. ¹⁵³ICAN Institute for Cardiometabolism and Nutrition, Paris, France. ¹⁵⁴Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA. ¹⁵⁵Group Health Research Institute, Group Health Cooperative, Seattle, WA. USA. ¹⁵⁶Seattle Epidemiologic Research and Information Center, VA Office of Research and Development, Seattle, WA, USA. ¹⁵⁷Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA. ¹⁵⁸Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway. ¹⁵⁹Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore. ¹⁶⁰National Heart and Lung Institute, Imperial College London, London, UK. ¹⁶¹Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan. ¹⁶²Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA. ¹⁶³Department of Cardiology, University Medical Center Groningen, University of Groningen, Netherlands. ¹⁶⁴MRC‐PHE Centre for Environment and Health, School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, London, UK. ¹⁶⁵Department of Epidemiology and Biostatistics, Imperial College London, London, UK. ¹⁶⁶Department of Cardiology, Ealing Hospital NHS Trust, Southall, UK. ¹⁶⁷National Heart, Lung and Blood Research Institute, Division of Intramural Research, Population Sciences Branch, Framingham, MA, USA. ¹⁶⁹Department of Phamaceutical Sciences, Collge of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. ¹⁷⁰Oklahoma Center for Neuroscience, Oklahoma City, OK, USA. ¹⁷¹Department of Pathology and Genetics, Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. ¹⁷²Department of Neurology, Helsinki University Hospital, Helsinki, Finland. ¹⁷³Clinical Neurosciences, Neurology, University of Helsinki, Helsinki, Finland. ¹⁷⁴Department of Neurology, University of Washington, Seattle, WA, USA. ¹⁷⁵Albrecht Kossel Institute, University Clinic of Rostock, Rostock, Germany. ¹⁷⁶Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. ¹⁷⁷Department of Genetics, Perelman School of Medicine, University of Pennsylvania, PA, USA. ¹⁷⁸Faculty of Medicine, University of Iceland, Reykjavik, Iceland. ¹⁷⁹Departments of Neurology and Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA. ¹⁸⁰Department of Neurology, Boston University School of Medicine, Boston, MA, USA. ¹⁸¹Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA. ¹⁸²Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. ¹⁸³Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. ¹⁸⁴German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. ¹⁸⁵Boston University School of Medicine, Boston, MA, USA. ¹⁸⁶University of Kentucky College of Public Health, Lexington, KY, USA. ¹⁸⁷University of Newcastle and Hunter Medical Research Institute, New Lambton, Australia. ¹⁸⁸Univ. Montpellier, Inserm, U1061, Montpellier, France. ¹⁸⁹Centre for Research in Environmental Epidemiology, Barcelona, Spain. ¹⁹⁰Department of Neurology, Università degli Studi di Perugia, Umbria, Italy. ¹⁹¹Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. ¹⁹²Broad Institute, Cambridge, MA, USA. ¹⁹³Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France. ¹⁹⁴Bordeaux University Hospital, Department of Neurology, Memory Clinic, Bordeaux, France. ¹⁹⁵Neurovascular Research Laboratory. Vall d'Hebron Institut of Research, Neurology and Medicine Departments‐Universitat Autònoma de Barcelona. Vall d’Hebrón Hospital, Barcelona, Spain. ¹⁹⁶University Medicine Greifswald, Department of Internal Medicine B, Greifswald, Germany. ¹⁹⁷DZHK, Greifswald, Germany. ¹⁹⁸Robertson Center for Biostatistics, University of Glasgow, Glasgow, UK. ¹⁹⁹Hero DMC Heart Institute, Dayanand Medical College & Hospital, Ludhiana, India. ²⁰⁰Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. ²⁰¹Karolinska Institutet, Stockholm, Sweden. ²⁰²Division of Emergency Medicine, and Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. ²⁰³Tohoku Medical Megabank Organization, Sendai, Japan. ²⁰⁴Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA. ²⁰⁵Department of Public Health and Caring Sciences / Geriatrics, Uppsala University, Uppsala, Sweden. ²⁰⁶Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan. ²⁰⁷Department of Internal Medicine and the Center for Clinical and Translational Science, The Ohio State University, Columbus, OH, USA. ²⁰⁸Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Goteborg, Sweden. ²⁰⁹Department of Basic and Clinical Neurosciences, King's College London, London, UK. ²¹⁰Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Japan. ²¹¹Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan. ²¹²Landspitali National University Hospital, Departments of Neurology & Radiology, Reykjavik, Iceland. ²¹³Department of Neurology, Heidelberg University Hospital, Germany. ²¹⁴Department of Neurology, Erasmus University Medical Center. ²¹⁵Hospital Universitari Mutua Terrassa, Terrassa (Barcelona), Spain. ²¹⁶Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA. ²¹⁷John Hunter Hospital, Hunter Medical Research Institute and University of Newcastle, Newcastle, NSW, Australia. ²¹⁸Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, UK. ²¹⁹Department of Medical Sciences, Uppsala University, Uppsala, Sweden. ²²⁰Genetic and Genomic Epidemiology Unit, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. ²²¹The Wellcome Trust Centre for Human Genetics, Oxford, UK. ²²²Beth Israel Deaconess Medical Center, Boston, MA, USA. ²²³Wake Forest School of Medicine, Wake Forest, NC, USA. ²²⁴Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA. ²²⁵BioBank Japan, Laboratory of Clinical Sequencing, Department of Computational biology and medical Sciences, Graduate school of Frontier Sciences, The University of Tokyo, Tokyo, Japan ²²⁶Neurovascular Research Laboratory, Vall d'Hebron Institut of Research, Neurology and Medicine Departments‐Universitat Autònoma de Barcelona. Vall d’Hebrón Hospital, Barcelona, Spain. ²²⁷Department of Biostatistics, University of Liverpool, Liverpool, UK. ²²⁸Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. ²²⁹Institute of Genetic Epidemiology, Helmholtz Zentrum München ‐ German Research Center for Environmental Health, Neuherberg, Germany. ²³⁰Department of Medicine I, Ludwig‐Maximilians‐Universität, Munich, Germany. ²³¹DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. ²³²Department of Cerebrovascular Diseases, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milano, Italy. ²³³Karolinska Institutet, MEB, Stockholm, Sweden. ²³⁴University of Tartu, Estonian Genome Center, Tartu, Estonia, Tartu, Estonia. ²³⁵Department of Clinical and Experimental Sciences, Neurology Clinic, University of Brescia, Italy. ²³⁶Translational Genomics Unit, Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy. ²³⁷Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain. ²³⁸Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addictions, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain. ²³⁹Department of Neurology, IMIM‐Hospital del Mar, and Universitat Autònoma de Barcelona, Spain. ²⁴⁰IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. ²⁴¹National Institute for Health Research Comprehensive Biomedical Research Centre, Guy's & St. Thomas’ NHS Foundation Trust and King's College London, London, UK. ²⁴²Division of Health and Social Care Research, King's College London, London, UK. ²⁴³FIMM‐Institute for Molecular Medicine Finland, Helsinki, Finland. ²⁴⁴THL‐National Institute for Health and Welfare, Helsinki, Finland. ²⁴⁵Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate, Japan. ²⁴⁶BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, Glasgow, UK. ²⁴⁷deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. ²⁴⁸Icelandic Heart Association, Reykjavik, Iceland. ²⁴⁹Institute of Biomedicine, the Sahlgrenska Academy at University of Gothenburg, Goteborg, Sweden. ²⁵⁰Department of Epidemiology, University of Maryland School of Medicine, Baltimore, MD, USA. ²⁵¹Institute of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, Glasgow, UK. ²⁵²Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, Germany. ²⁵³Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan. ²⁵⁴Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ²⁵⁵University Medicine Greifswald, Institute for Community Medicine, SHIP‐KEF, Greifswald, Germany. ²⁵⁶Department of Neurology, Caen University Hospital, Caen, France. ²⁵⁷University of Caen Normandy, Caen, France. ²⁵⁸Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands. ²⁵⁹Landspitali University Hospital, Reykjavik, Iceland. ²⁶⁰Survey Research Center, University of Michigan, Ann Arbor, MI, USA. ²⁶¹University of Virginia Department of Neurology, Charlottesville, VA, USA.

Temprano‐Sagrera G, Sitlani CM, Bone WP, et al. Multi‐phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations. J Thromb Haemost. 2022;20:1331–1349. doi: 10.1111/jth.15698